In terms of weight loss, though, youll typically see gradual progress over the course of several weeks
Tng cng h thng min dch, gip c th khe mnh
T2DM, CVD) Clinical Development A phase 1 study with healthy or obese subjects is completed NCT06481098 A phase 2 study with obese subjects is currently ongoing in the US NCT07205900 A phase 2 study with subjects with type 2 diabetes mellitus is currently ongoing in the US NCT07527650 Publications Poster Cross-Species Pharmacokinetic Comparison and Human PK Prediction of HM15275, A Novel Long-Acting GLP1/GIP/GLUCAGON Triple Agonist for Treatment of Obesity International Society for the Study of Xenobiotics (ISSX), 2026 Download Poster Efficacy and Safety of HM15275, a Novel Long-Acting Triple Agonist in Adults With Obesity ObesityWeek, 2025 Download Poster Mechanistic insights into the potent anti-obesity effects of HM15275, a novel long-acting GLP-1/GIP/glucagon triple agonist European Association for the Study of Diabetes (EASD), 2025 Download Poster Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist: Preliminary Results from a Phase 1 Study American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Robust Anti-obesity Effect and Mechanistic Insights of HM15275, A Novel Long-acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Metabolic Adaptation of Liver with Treatment of HM15275, A Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Supporting Lean Mass Preservation American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Potent weight loss effect and mechanism of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in animal model of obesity ObesityWeek, 2024 Download Poster Therapeutic potential of HM15275, a novel long-acting GLP-1/GIP/GCG triple agonist, in animal models of heart failure American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Potent weight loss and favorable glycemic control effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in animal models American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Potential cardioprotective effects of HM15275, a novel, long-acting GLP-1/GIP/GCG triple agonist, in animal models of hypertension American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Nephroprotective effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in preclinical models of acute and chronic kidney diseases American Diabetes Association (ADA) Scientific Sessions, 2024 Download
How Do GLP-1 Receptor Agonist Medications Work
Clarify how often you will need follow-up visits, lab tests, or monitoring while on tirzepatide to ensure your safety throughout the treatment
The goal is to find a tolerable, sustainable rhythm on the medication
